Asymptomatic TB With Innovative Modified Short-course Regimens

Prior treatment

• 9\. Prior anti-TB treatment for more than one week in the past six months;

Other illness

• 1\. Combined extrapulmonary tuberculosis;
• 3\. Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any one or more of the following: rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones;
• 7\. Known allergic or intolerant to any of the study drugs;
• 10.Known history of epilepsy, uncontrolled diabetes;

Lab values

• 4\. Individuals with impaired liver function (alanine transaminase \[ALT\] or total bilirubin \[TBIL\] more than 2.5 times the upper limit of normal) or combined with liver cirrhosis;
• 5\. Hemoglobin is less than 70g/L, or platelet is less than 50\*10\^9/L;
• 6\. Estimated Glomerular Filtration Rate (eGFR) is less than 30 mL/min/1.73m2;
• 11.For HIV-positive subjects, T-lymphocyte (CD4 cell) counts less than 100 cells/mm3;

Other

• 2\. Induviduals with extensive lesion (lesion involvement exceeding 50% or the aggregate diameter of all cavities exceeding 6 cm) ;
• 8\. Pregnant or breast-feeding;
• 12\. Unable to tolerant oral treatment.

• 1\. Age between 14 to 80 years;
• 2\. Male or female;
• 3\. Willing to provide signed informed consent, or parental consent and participant assent;
• 4\. Individuals with respiratory tract specimen (including sputum/bronchoalveolar lavage fluid/lung tissue) positive for acid-fast bacilli smear/culture/molecular amplification for M. tuberculosis;
• 5\. No unexplained TB-suggestive symptoms in the three months prior to screening, including cough lasting more than two weeks, night sweats, fever or weight loss;
• 6\. If non-menopausal woman, agree to use or have used effective contraception during treatment.